[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq\u00ae) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brady J.D., LLM", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 923235, "exercisedValue": 0, "unexercisedValue": 262204}, {"maxAge": 1, "name": "Mr. Nicholas  Maestas", "age": 42, "title": "VP of Strategy & Finance and Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 465429, "exercisedValue": 0, "unexercisedValue": 67328}, {"maxAge": 1, "name": "Dr. Samuel  Whiting M.D., Ph.D.", "age": 57, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 667651, "exercisedValue": 0, "unexercisedValue": 93438}, {"maxAge": 1, "name": "Mr. Justin  Trojanowski", "age": 35, "title": "Corporate Controller, Treasurer & Principal Accounting Officer", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lindsay  Young", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.06, "open": 1.06, "dayLow": 1.05, "dayHigh": 1.13, "regularMarketPreviousClose": 1.06, "regularMarketOpen": 1.06, "regularMarketDayLow": 1.05, "regularMarketDayHigh": 1.13, "beta": -2.899, "forwardPE": -0.7898551, "volume": 3577000, "regularMarketVolume": 3577000, "averageVolume": 4421660, "averageVolume10days": 8310940, "averageDailyVolume10Day": 8310940, "marketCap": 27476502, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 6.0, "fiftyDayAverage": 1.2935, "twoHundredDayAverage": 2.696285, "currency": "USD", "enterpriseValue": 16607493, "floatShares": 21506280, "sharesOutstanding": 25207800, "sharesShort": 3720057, "sharesShortPriorMonth": 1924302, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.1476, "heldPercentInsiders": 0.00242, "heldPercentInstitutions": 0.22432, "shortRatio": 1.03, "shortPercentOfFloat": 0.17799999, "bookValue": 0.692, "priceToBook": 1.5751446, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -31748000, "trailingEps": -1.6, "forwardEps": -1.38, "lastSplitFactor": "1:15", "lastSplitDate": 1624838400, "enterpriseToEbitda": -0.532, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TPST", "underlyingSymbol": "TPST", "shortName": "Tempest Therapeutics, Inc.", "longName": "Tempest Therapeutics, Inc.", "firstTradeDateEpochUtc": 1352730600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d54d822e-cd83-39cb-b46d-5c9b6edb9502", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.09, "targetHighPrice": 47.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.6, "targetMedianPrice": 13.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 31124000, "totalCashPerShare": 1.235, "ebitda": -31246000, "totalDebt": 20255000, "quickRatio": 2.138, "currentRatio": 2.167, "debtToEquity": 119.576, "returnOnAssets": -0.54282004, "returnOnEquity": -2.8926198, "freeCashflow": -15198000, "operatingCashflow": -25358000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]